Results and adverse events of personalized peptide receptor radionuclide therapy with (90)Yttrium and (177)Lutetium in 1048 patients with neuroendocrine neoplasms

INTRODUCTION: Peptide receptor radionuclide therapy (PRRT) of patients with somatostatin receptor expressing neuroendocrine neoplasms has shown promising results in clinical trials and a recently published phase III study. METHODS: In our center, 2294 patients were screened between 2004 and 2014 by...

Descripción completa

Detalles Bibliográficos
Autores principales: Baum, Richard P., Kulkarni, Harshad R., Singh, Aviral, Kaemmerer, Daniel, Mueller, Dirk, Prasad, Vikas, Hommann, Merten, Robiller, Franz C., Niepsch, Karin, Franz, Holger, Jochems, Arthur, Lambin, Philippe, Hörsch, Dieter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908296/
https://www.ncbi.nlm.nih.gov/pubmed/29682195
http://dx.doi.org/10.18632/oncotarget.24524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908296/
https://www.ncbi.nlm.nih.gov/pubmed/29682195
http://dx.doi.org/10.18632/oncotarget.24524

Ejemplares similares